NRTIs |
Abacavir (ABC) |
HLA-B*5701 |
Hypersensitivity Reaction Syndrome |
Tenofovir (TDF) |
ABCC2-MRP2 (1249G > A) |
Increased risk of tubulopathy |
Lamivudine (3TC) |
MRP4 4131T > G |
Increased plasma concentrations |
Zidovudine (AZT) |
MRP4 3724 G > A |
Increased plasma concentrations |
Didanosine (ddI) |
CFTR 1717-1G > A, |
Higher risk of pancreatitis |
|
IV585T, |
Didanosine (ddI), Zalcitabine (ddC), Stavudine (d4T) |
SPINK-1 112C > T |
Leber’s Hereditary Optic Neuropathy, Peripheral Neuropathy |
MTND1 LHON4216C, |
|
MTND2 LHON4917G |
NNRTIs |
Nevirapine (NVP) |
HLA-B*58:01, *15:02, *35:05 |
Cutaneous rash, SJS/TEN |
|
ABCC10rs2125739, CYP2B6 516G > T |
Increased plasma concentration, hepatotoxicity |
|
|
Reduced risk of hepatotoxicity |
Efavirenz (EFV) |
MDR1 3435C > T |
Higher plasma concentrations, SNC side effects |
|
CYP2B6 G516T, T983C |
PIs |
Atazanavir (ATV) |
UGT1A1*28, MDR1 3435C/C |
Hyperbilirubinemia and jaundice |
All PIs |
TNF gene 238G > A |
Early onset of lypodistrophy |
|
APOA5 (1131T > C, 64G > C), |
High risk of dyslipidemia |
|
APOC3 (482C > T, 455C > T, 3238C > G) |
|
ABCA1 2962A > G |
|
APOE (ε2, ε3 haplotypes) |
Others |
Maraviroc (MVC) |
SLC01B1 521T > C (rs4149056) |
Increased plasma concentrations |
Raltegravir (RAL) |
UGT1A1*28 |
Increased plasma concentrations |